JPRN-UMIN000052314
Recruiting
未知
Development of Novel Immunotherapy for Cancer - Development of Novel Immunotherapy for Cancer
Ehime University Graduate School of Medicine0 sites20 target enrollmentOctober 1, 2023
Conditionsiquid and Solid Tumors
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- iquid and Solid Tumors
- Sponsor
- Ehime University Graduate School of Medicine
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Donors whose Hb values are less than 9\.0 g/dL.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerOvarian CancerFallopian Tube CancerPeritoneal CancerNCT01416038ImmunoVaccine Technologies, Inc. (IMV Inc.)19
Recruiting
Not Applicable
Development of new approaches for immunotherapy of non-small cell lung cancerC34Malignant neoplasm of bronchus and lungDRKS00029641Molekulare PneumologieUniversitätsklinikum Erlangen
Recruiting
Not Applicable
POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging.NSCLCskin cancer (melanoma)10027476NL-OMON51740niversitair Medisch Centrum Groningen200
Completed
Phase 2
Dendritic Cell Vaccine for the treatment of Stage IIIb Cervical Cancer patientsHealth Condition 1: C53- Malignant neoplasm of cervix uteriCTRI/2016/12/007530Department of Science and Technology DST54
Unknown
Not Applicable
Feasibility 'innate' allogeneic stem cells transplantioHematological malignancies (hematologische maligniteiten)Allogeneic stem cells transplantation (allogene stamcel transplantatie)Innate immune system (aangeboren immuunsysteem)NL-OMON25484MC UtrechtHeidelberglaan 1003584 CX Utrecht35